Sun Pharmaceutical Industries (SUNPHARMA) Weekly Analysis
Price & Volume
The stock price declined by 0.96% during the week ending June 5, 2026. Trading activity was relatively quiet, with the total volume dropping by 34.43% compared to the previous week. The price remained near the 50-day moving average, which is the average closing price over the last 50 trading days.
Technicals
The stock price closed at 1782.0 this week, reflecting a 0.96% decline. The 20-week and 50-week simple moving averages (SMAs)—which track the average price over specific periods to identify trends—both maintain upward slopes. Momentum indicators show a cooling trend, with the Relative Strength Index (RSI) at 43.27, indicating a decrease in buying pressure. The Moving Average Convergence Divergence (MACD) histogram is negative, suggesting a shift in momentum. Volatility, measured by Bollinger Band width, has expanded to 8.35%, indicating a wider range of price movement compared to the previous week.
Fundamentals
Sun Pharmaceutical Industries reported a notable increase in net profit, which grew 25.8% year-over-year (YoY) to ₹2710 million in the March 2026 quarter. Revenue also saw a positive YoY growth of 12.8%. The operating margin remained strong at 27.0% for the quarter. However, sequential performance showed a dip, with net profit declining 19.8% quarter-over-quarter (QoQ). The company currently trades at a Price-to-Earnings (PE) ratio of 142.5x and a Price-to-Book (PB) ratio of 19.1x.
News
During the week ending June 5, 2026, the pharmaceutical sector maintained its position as a favored theme among market analysts. Multiple experts, including Devina Mehra, Rohit Srivastava, and Gautam Shah, highlighted the sector's resilience and long-term appeal amidst broader market volatility. While Indian companies generally outperformed fourth-quarter earnings expectations, analysts noted that macroeconomic pressures, such as geopolitical tensions and energy concerns, continued to influence market sentiment. Although specific company-level developments for Sun Pharma were not reported during this period, the sector remained a focal point for investors seeking stability within the current market environment. Overall, the industry was characterized by sustained interest from market observers despite ongoing global economic uncertainties.
Events
Sun Pharmaceutical Industries reported a 13.6% revenue increase to ₹1,45,598 million for Q4 FY26 and declared a final dividend of ₹5 per share. The company achieved strong growth in its global innovative medicines and India formulations business, while maintaining a net cash position of $3.2 billion.
Sun Pharmaceutical Industries Limited has announced its schedule for upcoming analyst and institutional investor meetings in Mumbai, scheduled between June 1 and June 4, 2026.
Sun Pharmaceutical Industries Limited has submitted an application to stock exchanges to reclassify specific members of its 'Promoter Group' into the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharma announced that it will present updated long-term follow-up data for its drug UNLOXCYT (cosibelimab-ipdl) at the 2026 ASCO Annual Meeting. The study of patients with locally advanced cutaneous squamous cell carcinoma demonstrated durable clinical responses and a manageable safety profile.
Sun Pharmaceutical Industries Limited has announced its participation in the 360 ONE Capital 16th Annual Investor Conference scheduled for 27 May 2026 in Mumbai. The company confirmed that no unpublished price-sensitive information will be shared during these meetings.
Sun Pharmaceutical Industries Limited released an investor presentation in April 2026 announcing the proposed acquisition of Organon & Co. This strategic move aims to expand Sun Pharma's global footprint and strengthen its portfolio in Women’s Health, biosimilars, and established brands.
The provided source URL for the BSE Ltd. corporate announcement is currently inactive and does not contain accessible financial or event-related information.
Sun Pharmaceutical Industries held a conference call to discuss the details and strategic rationale behind a new company acquisition.
CRISIL has placed Sun Pharmaceutical Industries Limited's long-term bank facilities on 'Rating Watch with Developing Implications' following its $11.75 billion acquisition of Organon & Co. This move reflects the significant debt-funded nature of the transaction and the operational complexities involved in the integration.
ICRA has issued a credit rating rationale for the company as of May 5, 2026, providing an assessment of its financial stability and creditworthiness for stakeholders.
Sun Pharmaceutical Industries Limited has announced its schedule for upcoming analyst and institutional investor meetings in Mumbai, scheduled between June 1 and June 4, 2026.
Sun Pharmaceutical Industries Limited has submitted an application to stock exchanges to reclassify specific members of its 'Promoter Group' into the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharma announced that it will present updated long-term follow-up data for its drug UNLOXCYT (cosibelimab-ipdl) at the 2026 ASCO Annual Meeting. The study of patients with locally advanced cutaneous squamous cell carcinoma demonstrated durable clinical responses and a manageable safety profile.
Sun Pharmaceutical Industries Limited has announced its participation in the 360 ONE Capital 16th Annual Investor Conference scheduled for 27 May 2026 in Mumbai. The company confirmed that no unpublished price-sensitive information will be shared during these meetings.
Sun Pharmaceutical Industries Limited released an investor presentation in April 2026 announcing the proposed acquisition of Organon & Co. This strategic move aims to expand Sun Pharma's global footprint and strengthen its portfolio in Women’s Health, biosimilars, and established brands.
The provided source URL for the BSE Ltd. corporate announcement is currently inactive and does not contain accessible financial or event-related information.
Sun Pharmaceutical Industries held a conference call to discuss the details and strategic rationale behind a new company acquisition.
CRISIL has placed Sun Pharmaceutical Industries Limited's long-term bank facilities on 'Rating Watch with Developing Implications' following its $11.75 billion acquisition of Organon & Co. This move reflects the significant debt-funded nature of the transaction and the operational complexities involved in the integration.
ICRA has issued a credit rating rationale for the company as of May 5, 2026, providing an assessment of its financial stability and creditworthiness for stakeholders.
Weekly Snapshot
Highlights
- The stock declined by 0.96% this week as trading volume fell by 34.43%, reflecting a period of consolidation and lower market participation.
- CRISIL Ratings placed long-term bank facilities on 'Rating Watch with Developing Implications' following the $11.75 billion acquisition of Organon & Co.
- The company filed an application to reclassify specific members of its 'Promoter Group' into the 'Public' category, aligning with SEBI Listing Regulations.
- Sun Pharma announced plans to present updated long-term data for its drug UNLOXCYT at the 2026 ASCO Annual Meeting, highlighting durable clinical responses.
- Technical indicators show a cooling trend with the RSI at 43.27 and a negative MACD histogram, suggesting a shift in short-term momentum.
What This Means
The stock is currently in a consolidation phase, characterized by lower trading volumes and a slight decline in price. While the stock remains above its 200-day moving average, it is currently testing its 50-day moving average, a key technical level for market participants. The recent credit rating watch reflects the financial impact of the significant debt-funded acquisition of Organon & Co., which remains a focal point for investors assessing the company's long-term leverage and integration risks.
Latest Quarter Info
For the Mar 2026 period, the company reported revenue of 14612.0. Revenue demonstrated positive year-over-year momentum, increasing by 12.76%, though it experienced a quarter-over-quarter decline of 5.86%. Profitability trends show a net profit of 2710.0. Operating margin remained stable at 27.0%. The mix of signals indicates strong annual growth in net profit, up 25.81% year-over-year, and a corresponding EPS increase of 26.23%. However, quarter-over-quarter performance for net profit and EPS saw significant decreases of 19.85% and 19.44% respectively, suggesting a potential short-term headwind or a pull-forward of sales in the prior quarter.